Theriva Biologics Inc (TOVX) — 13F Holders Deep Dive (Q2 2026)

TOVX ranks #7805 out of 37507 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

TOVX is a disclosed holding of Jane Street (Jane Street Group), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

26 institutions disclose a position in TOVX, but none treat it as a major bet — even Ground Swell Capital, LLC, its most concentrated holder, allocates just 0.0% of its own portfolio to it.

SBI Securities Co., Ltd. has added to its TOVX position for two straight quarters, increasing it by $78.0 to reach $90.0 today.

TOVX reported a net loss of $11.6M over the trailing twelve months.

• Not yet profitable — net loss of $11.6M over the trailing twelve months
• Net income improved year over year, from -$29.6M to -$11.6M
• Operating cash flow was negative, using $16.7M in cash
• Current ratio of 1.74x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.49x equity — within a conventional range